Best of ASCO® Montreal 2024: GU Cancer – Dr. Cristiano Ferrario

Icon Chair Speaker

Co-Chairs

Dr. Jamil Asselah
Dr. Kim Ma

Icon Chair Speaker

Speakers

Dr. Cristiano Ferrario

Studies/trials discussed:

  • A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.
  • CYCLONE 2: A Phase 3 study of Abemaciclib with Abiraterone in Patients with mCRPC
  • Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
  • A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
  • Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.
  • A multicenter phase II study of modified FOLFIRINOX for first-line treatment for advanced urachal cancer (ULTMA; KCSG GU20-03).
  • A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.